Updated time: 2022-02-17 08:08:05
Vascular endothelial growth factor receptor 2 (VEGFR2) is highly expressed in tumor-associated endothelial cells to modulate angiogenesis for tumor growth. VEGFR2 expression is also found on the cell surface of several types of tumor. Here we identified and characterized several human single chain variable fragment (scFv) antibodies against VEGFR2 using phage display. Two of these scFvs, R2S8 and R2S12, inhibited interaction of VEGF-A/VEGFR2 and neutralized VEGF-A-induced VEGFR2 phosphorylation. Binding epitope mapping studies demonstrated that both scFvs bind to a unique epitope in domain 3 of human VEGFR2. The binding affinity of R2S12 was further improved by affinity maturation and engineered to a fully human antibody, named anti-VEGFR2-AF hAb. Compared to FDA-approved anti-VEGFR2 human antibody IMC-1121B (ramucirumab), anti-VEGFR2-AF hAb possessed significantly superior antagonizing activity and suppressed VEGF-A-mediated tubule formation in vitro. In PC-3-derived xenograft mouse models, treatment with anti-VEGFR2-AF hAb monotherapy and combination with docetaxel repressed tumor growth and angiogenesis more effectively than treatment with IMC-1121B. In the mice bearing HL-60-derived leukemia, anti-VEGFR2-AF hAb exhibited more significant efficacy than IMC-1121B in prolonging survival and decreasing metastasis.
This invention has four unique features shown below. First, we identified a novel human antibody against VEGFR2 with higher affinity, anti-VEGFR2-AF hAb, which has distinct CDR sequences. Second, we further identified the binding epitope of anti-VEGFR2-AF hAb and found it is different from the binding epitope of IMC-1121B. Third, in vitro experiments we demonstrated that the binding, antagonistic and anti-angiogenic activity of anti-VEGFR2-AF hAb was better than IMC-1121B. Fourth, by head-to-head comparison therapeutic efficacy of anti-VEGFR2-AF hAb was superior to IMC-1121B in human prostate and leukemia murine models. Taken together, anti-VEGFR2-AF hAb has highly clinical potential for cancer therapy by exerting anti-angiogenesis or by directly targeting VEGFR2-expressing tumor cells.
10A-1040307
AU 2016249991、US 10196447 B2、TW I621629、 JP 6542383、SG 11201707949X、EP 3283528 B1、CN ZL-2016-8-0020787.5、IN 382204、MX 388174
- Development of diagnostic reagents for cancer.
- Development of anti-angiogenic and targeted cancer therapy.
Han-Chung Wu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Anti-VEGFR2 human antibody for anti-angiogenic and targeted cancer therapy